

13th January, 2025

To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001
Scrip Code: 511509

Dear Sir/Madam,

Subject : Launch of Large Animal Facility

We are pleased to announce a significant milestone in Vivo Bio Tech's journey of expansion and growth.

Vivo Bio Tech Limited has successfully secured approval from the Committee for the Purpose of Control and Supervision of Experiments on Animals (CPCSEA), obtained funding from a financial institution, and completed the development of a state-of-the-art large animal facility. This advanced 15,000 sq. ft. facility, co-funded through internal accruals and institutional debt, is designed to house, breed, and conduct studies on canines, pigs, mini-pigs, sheep, and goats.

Operations have already commenced at the facility, which offers a wide range of services, including Pharmacokinetic (PK), Pharmacodynamic (PD), Surgical Studies, and Toxicology Studies. These services are being provided to an expanding list of major pharmaceutical and bio-pharmaceutical companies.

This new capability significantly strengthens Vivo Bio Tech's existing ecosystem, which encompasses In-vitro and In-vivo Small Animal Studies, Eco-Toxicology, Analytical, and Bio-analytical services. The addition of this large animal facility enables us to deliver comprehensive Investigational New Drug (IND) packages to pharmaceutical and biotech companies worldwide. Vivo Bio Tech now proudly joins an elite group of Contract Research Organizations (CROs) capable of supporting diverse research and development needs across both large and small animal models.

Furthermore, the company is committed to expanding its capabilities to position itself as a joint discovery partner for large pharmaceutical organizations. Future developments will be shared as and when they materialize.

This announcement is for your information and records.

Thanking You,
Yours faithfully,
For Vivo Bio Tech Limited

A V Kiran
Company Secretary